Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Phase III Data Give Medicines Company's Carbavance A Chance To Best Antibiotic Competitors

Executive Summary

The Medicines Co. is a few years behind its most recent beta-lactamase inhibitor competitors, but its antibiotic Carbavance is the only one with pivotal data that show superiority to a well-known drug in the same class for the treatment of hospital-based urinary tract infections.


Related Content

US Approval Of Vabomere Could Help Alleviate TMC's Financial Troubles
Keeping Track: US FDA Files Another Pfizer Cancer Biologic And TMC's New Antibiotic
The Medicines Co Sells CV Products To Fund Pipeline
Actavis antibiotic combo Avycaz OK'd for 2 infections
Cubist wins FDA nod for antibiotic Zerbaxa
BARDA backs Medicines/Rempex antibiotic with $90m award
Medicines Company gains anti-infectives in $140m Rempex buy


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts